Testing effectiveness (Phase 2)Study completedNCT01904682What this trial is testingOral Rigosertib in Low Risk MDS Patients Refractory to ESAsWho this might be right forMyelodysplastic Syndromes Traws Pharma, Inc. 45
Early research (Phase 1)Study completedNCT01062152What this trial is testingDose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Who this might be right forMyelodysplastic Syndrome Telik 19
Testing effectiveness (Phase 2)Study completedNCT00418665What this trial is testingA Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving RevlimidWho this might be right forMyelodysplastic SyndromesThrombocytopenia Amgen 39
Testing effectiveness (Phase 2)Looking for participantsNCT05731245What this trial is testingRopeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk MyelofibrosisWho this might be right forPre-fibrotic Myelofibrosis National Taiwan University Hospital 50
Testing effectiveness (Phase 2)Study completedNCT01338337What this trial is testingStudy of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent AnaemiaWho this might be right forMyelodysplastic Syndrome (MDS) Asociación Andaluza de Hematología y Hemoterapia 40
Testing effectiveness (Phase 2)Study completedNCT00531232What this trial is testingA Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)Who this might be right forMyelodysplastic SyndromesSecondary Acute Myeloid Leukemia (AML) Genzyme, a Sanofi Company 38
Testing effectiveness (Phase 2)Study completedNCT01891968What this trial is testingBortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 ActivationWho this might be right forLeukemia M.D. Anderson Cancer Center 15
Early research (Phase 1)WithdrawnNCT02075034What this trial is testingThree Dosing Schedules of Oral Rigosertib in MDS PatientsWho this might be right forMyelodysplastic Syndrome Traws Pharma, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT00939159What this trial is testingStudy of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)Who this might be right forMyelodysplastic Syndrome M.D. Anderson Cancer Center 17
Testing effectiveness (Phase 2)Ended earlyNCT00809185What this trial is testingRAD001(Everolimus) in Treating Patients With Myelodysplastic SyndromesWho this might be right forMyelodysplastic Syndromes Case Comprehensive Cancer Center 7
Large-scale testing (Phase 3)Study completedNCT01381809What this trial is testingAn Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic SyndromesWho this might be right forMyelodysplastic Syndromes Janssen-Cilag International NV 130
Testing effectiveness (Phase 2)Ended earlyNCT01222195What this trial is testingLenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)Who this might be right forLeukemia M.D. Anderson Cancer Center 1
Testing effectiveness (Phase 2)Study completedNCT00303472What this trial is testingDetermination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)Who this might be right forThrombocytopeniaMDSMyelodysplastic Syndromes+1 more Amgen 72
Testing effectiveness (Phase 2)Ended earlyNCT01513317What this trial is testingA Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndrome Janssen Research & Development, LLC 76
Testing effectiveness (Phase 2)Study completedNCT00906334What this trial is testingEfficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High RiskWho this might be right forMyelodysplastic Syndrome Traws Pharma, Inc. 14
Testing effectiveness (Phase 2)Ended earlyNCT00486720What this trial is testingPhase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)Who this might be right forMyelodysplastic SyndromesBlood DiseaseBone Marrow Disease Merck Sharp & Dohme LLC 22
Testing effectiveness (Phase 2)Study completedNCT02268383What this trial is testingExtension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)Who this might be right forMyelodysplastic Syndromes Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 75
Testing effectiveness (Phase 2)Study completedNCT03502668What this trial is testingPhase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDSWho this might be right forMyelodysplastic Syndromes Taiho Oncology, Inc. 160
Testing effectiveness (Phase 2)Ended earlyNCT01379274What this trial is testingA Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic SyndromesWho this might be right forMDS Rush University Medical Center 2
Early research (Phase 1)Study completedNCT00916227What this trial is testingARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndromes Array Biopharma, now a wholly owned subsidiary of Pfizer 45